GlassScriptPhysician profile
Gabriel P Kasper
NPI 1104233808
$406.88
in general payments reported to CMS, 2019-2025
11 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $173.49 | 2025 | Evenity, Prolia |
| Abbvie INC. | $35.53 | 2025 | |
| Recordati_rare_diseases_inc. | $33.68 | 2025 | Isturisa |
| Madrigal Pharmaceuticals | $27.32 | 2025 | Rezdiffra |
| Acella Pharmaceuticals, LLC | $24.08 | 2025 | NP Thyroid 60 |
| Sandoz INC. | $22.39 | 2025 | Jubbonti |
| Novo Nordisk INC | $21.26 | 2025 | Ozempic |
| Tolmar, INC. | $19.23 | 2025 | Jatenzo |
| Ascendis Pharma Endocrinology INC | $17.36 | 2025 | Yorvipath |
| Lilly USA, LLC | $16.85 | 2025 | Zepbound |
| Beta Bionics, INC. | $15.69 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.